Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic/Kyphon merger clears FTC

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's pending $3.9 billion acquisition of spinal device maker Kyphon clears Federal Trade Commission antitrust review, the firms announce Sept. 11. Inked in July, the merger deal will expand Medtronic's spinal business, adding Kyphon's flagship KyphX balloon kyphoplasty system for spinal compression fractures. However, a proposed consent decree is still pending with FTC related to Kyphon's earlier $220 million proposed deal to purchase Disc-O-Tech spine technology, which likely will require Kyphon's divestiture of "most, and potentially all," of the assets related to Disc-O-Tech's Confidence cement delivery system for vertebral compression fractures, Kyphon notes. Kyphon shareholders will meet Oct. 16 to vote on the proposed Medtronic merger, which also remains subject to antitrust review outside the United States and is expected to close in the first quarter of 2008 (1"The Gray Sheet" July 30, 2007, p. 3)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel